MacroGenics Inc (MGNX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9786)
◆英語タイトル:MacroGenics Inc (MGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9786
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:67
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
MacroGenics Inc (MacroGenics) is a clinical-stage biopharmaceutical company which focuses on the discovery, development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its pipeline includes product candidates for the treatment of solid tumors, breast and gastroesophageal cancers type 1 diabetes, HIV, leukemia; and DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; colorectal cancer; and b-cell malignancies. The company’s product candidates are based on three core proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and Fc Optimization Platform. It also works in collaboration with major pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities to develop product candidates. MacroGenics is headquartered in Rockville, Maryland, the US.

MacroGenics Inc (MGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MacroGenics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12
Partnerships 13
MacroGenics Enters into Agreement with Merck 13
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15
Licensing Agreements 17
Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17
Roche Enters into Licensing Agreement with MacroGenics 18
Incyte Enters into Licensing Agreement with MacroGenics 19
MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24
Equity Offering 26
MacroGenics Raises USD110 Million in Public Offering of Shares 26
Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28
Macrogenics Raises USD23.7 Million in Private Placement of Shares 29
MacroGenics Raises USD150 Million in Public Offering of Shares 30
MacroGenics Raises USD75 Million in Private Placement of Common Stock 32
MacroGenics Completes Public Offering Of Shares For US$82 Million 34
MacroGenics Completes IPO For US$92 Million 36
Asset Transactions 38
Provention Bio Acquires PRV-031 from MacroGenics 38
MacroGenics Inc – Key Competitors 39
MacroGenics Inc – Key Employees 40
MacroGenics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 07, 2018: MacroGenics provides update on corporate progress and 3rd quarter 2018 financial results 42
Aug 07, 2018: MacroGenics provides update on corporate progress and 2nd quarter 2018 financial results 44
May 07, 2018: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results 46
Feb 27, 2018: MacroGenics Reports 2017 Financial Results 48
Nov 08, 2017: MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results 50
Aug 02, 2017: MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results 52
May 03, 2017: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results 54
Feb 28, 2017: MacroGenics Provides Update on Corporate Progress and 2016 Financial Results 56
Corporate Communications 58
Nov 15, 2017: MacroGenics Names Dr. Jay Siegel to its Board of Directors 58
Jan 25, 2017: MacroGenics Announces Appointments to Board of Directors 59
Product News 60
11/10/2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017 60
09/05/2017: MacroGenics Provides Update on its DART candidate MGD013 61
Product Approvals 62
Sep 05, 2017: MacroGenics Advances Development of its DART candidate MGD014 62
Jan 05, 2017: MacroGenics’ MGD006 Granted Orphan Drug Status for AML by FDA 63
Clinical Trials 64
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017 64
Sep 10, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Presented at ESMO Congress 2017 65
Jul 17, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Accepted for Oral Presentation at ESMO Congress 2017 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
MacroGenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12
MacroGenics Enters into Agreement with Merck 13
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15
Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17
Roche Enters into Licensing Agreement with MacroGenics 18
Incyte Enters into Licensing Agreement with MacroGenics 19
MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24
MacroGenics Raises USD110 Million in Public Offering of Shares 26
Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28
Macrogenics Raises USD23.7 Million in Private Placement of Shares 29
MacroGenics Raises USD150 Million in Public Offering of Shares 30
MacroGenics Raises USD75 Million in Private Placement of Common Stock 32
MacroGenics Completes Public Offering Of Shares For US$82 Million 34
MacroGenics Completes IPO For US$92 Million 36
Provention Bio Acquires PRV-031 from MacroGenics 38
MacroGenics Inc, Key Competitors 39
MacroGenics Inc, Key Employees 40
MacroGenics Inc, Other Locations 41

List of Figures
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ MacroGenics Inc (MGNX):製薬・医療:M&Aディール及び事業提携情報(MacroGenics Inc (MGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆